Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo

Anticancer Research

Volumn 16, Issue 6 B, 1996, Pages 3673-3678

  Gutman, Mordechai ^a,b   Szold, Amir ^a   Ravid, Anat ^a   Lazauskas, Tuvia ^a   Merimsky, Ofer ^a   Klausner, Joseph M ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Angiogenesis; Animal models; Thalidomide; Therapy

Indexed keywords

PIPERIDINE DERIVATIVE; THALIDOMIDE;

ADAPTATION; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL; COLON CARCINOMA; CONTROLLED STUDY; CORNEA; FEMALE; GROWTH INHIBITION; IMMUNOMODULATION; INTRAGASTRIC DRUG ADMINISTRATION; LUNG METASTASIS; MELANOMA; MORPHOLOGY; MOUSE; NONHUMAN; PERITONEUM METASTASIS; PRIORITY JOURNAL; RABBIT; SOLID TUMOR; TREATMENT FAILURE; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; COLONIC NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; THALIDOMIDE; TUMOR CELLS, CULTURED;

EID: 0030499590     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Folkman J: How is blood vessel growth regulated in normal and neoplastic tissue? GHA Clowes Memorial Award Lecture, Cancer Res 46: 467-473, 1986.
2. Kolin EC and Liotta LA: Molecular insight into cancer invasion: strategies for prevention and intervention. Cancer Res 55: 1856-1862, 1995.
3. Fidler IJ and Ellis LM: The implication of angiogenesis for the biology and therapy of cancer metastasis. Cell 79: 185-188, 1994.
4. Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.
5. Weidner N, Carrol PR, Flax J, Blumenfeld W and Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143: 401-409, 1993.
6. Teicher BA, Holden SA, Gulshan A, Alvarez-Sotomayor E, Huang ZD, Chen YN and Brem H: Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other antiangiogenic agents. Int J Cancer 57: 1-6, 1994.
7. Kato T, Sato K, Kakinuma H and Matsuda Y: Enhanced suppression of tumor growth by combination of angiogenesis, inhibitor O-(chloroacetyl-carbamoy 1) funmagillol (TNP-470) and cytotoxic agents in mice. Cancer Res 54: 5143-5147, 1994.
8. D'Amato RJ, Loughman MS, Flynn E and Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082-4085, 1994.
9. Gutman M, Singh RK, Yoon S, Xie K, Bucana CD and Fidler IJ: Leukocyte-induced angiogenesis and subcutaneous growth of B16 melanoma. CancerBiotherapy 9: 163-170, 1994.
10. Kreisle RA and Ershler WB: Investigation of tumor angiogenesis in a mouse model: Role of host-tumor interactions. J Natl Cancer Inst 80: 849-854, 1988.
11. Auerbach R and Sidky YA: Nature of the stimulus leading to lymphocyte-induced angiogenesis. J Immunol 123: 751-754, 1979.
12. Ezekowitz RAB, Mulliken JB and Folkman J: Interferon-α-2a therapy for life threatening hemangiomas of infancy. N Engl J Med 326: 1456-1463, 1992.
13. Singh RK, Bucana CD, Gutman M, Fan D, Wilson MR and Fidler IJ: Organ sitedependent expression of basic fibroblast growth factor in human renal cell carcinoma cells. Am J Pathol 145: 365-374, 1994.
14. Singh RK, Gutman M, Bucana CD, Sanchez R, Llanza N and Fidler IJ: Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 92: 4562-4566, 1995.
15. Tolsma SS, Volpert OV, Good DJ, Fraziere WR, Polverini PJ and Bouck N: Peptides derived from two separate domains of the matrix protein thrombospondin-1 have antiangiogenic activity. J Cell Biol 122: 497-511, 1993.
16. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH and Folkman J: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328, 1994.
17. Hozi A, Sasada R, Matsutami E, Naito K, Sakura Y, Fujita T and Kozni Y: Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against humanbasic fibroblast growth factor. Cancer Res 51: 6180-6184, 1991.
18. Kim KJ, Li B, Winer J, Armanini M, Gillet N, Phillips HS and Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo Nature 362: 841-844, 1993.
19. Olson K, French T, Valley B and Fell J: A monoclonal antibody to human angiogenin suppresses tumor growth in athymic mice. Cancer Res 54: 4576-4579, 1994.
20. Seller MJ: Thalidomide and congenital abnormalities (letter). Lancet 2: 244, 1962.
21. Ching LM, Xu ZF, Gummer BH, Palmer BD, Joseph WR, Baguley BC: Effect of thalidomide on tumor necrosis factor production and anti-tumor-activity induced by 5,6 dimethylxanthenone-4-acetic acid. Br J Cancer 72: 339-343, 1995.
22. Sidkey YA and Auerbach R: Lymphocyte-induced angiogenesis in tumor bearing mice. Science 192: 1237-1238, 1976.
23. Morcira AL, Sampaio CP, Zmuidzinas A, Frindt P, Smith KA and Kaplan G: Thalidomide exerts its inhibitory action on tumor necrosis factor-α by enhancing mRNA degradation. J Exp Med 777: 1675-1680, 1993.
24. Fidler IJ: Critical factors in the biology of human cancer metastasis: Twenty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res 50: 6130-6138, 1990.
25. Gutman M, Singh RK, Xie K, Bucana CD and Fidler IJ: Regulation of interleukin-8 expression in human melanoma cells by the organ microenvironment. Cancer Res 55: 2470-2475, 1995.